LivaNova gets FDA approval for sleep apnea device

LivaNova has secured premarket approval from the U.S. Food and Drug Administration (FDA) for its aura6000 device, designed to treat sleep apnea. This regulatory milestone allows the company to bring its innovative solution to market, offering a new therapeutic option for patients suffering from this common sleep disorder. The approval underscores LivaNova's commitment to advancing medical technology and improving patient outcomes in respiratory care.